{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T04:09:16Z","timestamp":1745554156644,"version":"3.40.4"},"reference-count":13,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2005]]},"abstract":"<jats:p>This study was done to evaluate the in vitro activity of a new ketolide telithromycin in comparison with clarithromycin, erythromycin, moxifloxacin and levofloxacin against &lt;i&gt;Streptococcus pneumoniae&lt;\/i&gt; (n = 67),&lt;i&gt; Haemophilus influenzae &lt;\/i&gt;(n = 139)&lt;i&gt;, and Moraxella catarrhalis &lt;\/i&gt;(n = 46)collected between January and June 2003 in Hong Kong. Among the &lt;i&gt;H. influenzae&lt;\/i&gt; isolates, 25.2% produced \u03b2-lactamase, while 97.8% of &lt;i&gt;M. catarrhalis&lt;\/i&gt; isolates produced \u03b2-lactamase. Half of the &lt;i&gt;S. pneumoniae&lt;\/i&gt; isolates were nonsusceptible to penicillin, and 90.9% of these strains were resistant to clarithromycin and erythromycin. One (1.5%) &lt;i&gt;S. pneumoniae&lt;\/i&gt; strain was resistant to levofloxacin (MIC = 8 mg\/l) and all isolates were sensitive to moxifloxacin and telithromycin with MIC &lt;1 mg\/l. &lt;i&gt;H. influenzae &lt;\/i&gt;isolates were sensitive to all fluoroquinolones tested and 2.2% of &lt;i&gt;H. influenzae&lt;\/i&gt; were resistant to clarithromycin. &lt;i&gt;M. catarrhalis &lt;\/i&gt;isolates were sensitive except 1 strain which was resistant to levofloxacin (MIC = 4 mg\/l) and moxifloxacin (8 mg\/l). All &lt;i&gt;M. catarrhalis&lt;\/i&gt; strains were sensitive to telithromycin with MIC&lt;sub&gt;90&lt;\/sub&gt; = 0.5 mg\/l. Telithromycin demonstrated high activity and no resistance was found in all these major respiratory tract pathogens.<\/jats:p>","DOI":"10.1159\/000086575","type":"journal-article","created":{"date-parts":[[2005,6,24]],"date-time":"2005-06-24T08:57:06Z","timestamp":1119603426000},"page":"182-185","source":"Crossref","is-referenced-by-count":0,"title":["In vitro Activity of Telithromycin against Respiratory Tract Pathogens in Comparison with Other Antimicrobial Agents"],"prefix":"10.1159","volume":"51","author":[{"given":"Thomas K.W.","family":"Ling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching Ching","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2005,7,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1469-0691.2004.00752.x"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2Fdkg359"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1128%2FAAC.47.6.1875-1881.2003"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2Fdkg123"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2Fdkh339"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2F45.2.191"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159%2F000066769"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159%2F000077889"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2F48.5.659"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.ijantimicag.2003.07.002"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2Fdkh178"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016%2FS0140-6736%2877%2991562-8"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2Fdkh068"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/86575","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/86575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:13:13Z","timestamp":1745464393000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000086575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005]]},"references-count":13,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2005,7,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000086575","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"type":"print","value":"0009-3157"},{"type":"electronic","value":"1421-9794"}],"subject":[],"published":{"date-parts":[[2005]]}}}